Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination With Cytarabine Injection Versus Placebo in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed Acute Myeloid Leukemia

NCT06788756 is registered in ClinicalTrials.gov with Moleculin Biotech, Inc. as lead sponsor.

NCT NCT06788756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06788756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of L Annamycin for Injection in Combination With Cytarabine Injection Versus Placebo in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed Acute Myeloid Leukemia
Lead sponsor
Moleculin Biotech, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 12, 2025
Completion date
August 31, 2030
Enrollment
312 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia (aml)